{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from agent import graph\n",
    "\n",
    "state = graph.invoke({\"messages\": [{\"role\": \"user\", \"content\": \"Research on-going treatments for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\"}], \"max_research_loops\": 3, \"initial_search_query_count\": 3})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'messages': [HumanMessage(content='Research on-going treatments for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma', additional_kwargs={}, response_metadata={}, id='72769f98-bf9e-47c7-8d0d-571ee20637e0'),\n",
       "  AIMessage(content='As of July 2025, the treatment landscape for Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) and Small Lymphocytic Lymphoma (SLL) is characterized by a growing number of targeted therapies and innovative approaches designed to improve outcomes, especially for patients who have progressed on previous treatments [ajmc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI=). Treatment decisions are increasingly personalized, taking into account prior therapies, disease characteristics, and the patient\\'s overall health [lymphoma](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E=) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==4).\\n\\n### **FDA-Approved Therapies for R/R CLL/SLL**\\n\\nSeveral targeted agents have received FDA approval for treating R/R CLL/SLL, offering significant advancements over traditional chemotherapy.\\n\\n*   **CAR T-Cell Therapy**: Lisocabtagene maraleucel (liso-cel; Breyanzi) is the first CAR T-cell therapy approved for adults with R/R CLL/SLL. It is indicated for patients who have received at least two prior lines of therapy, including a Bruton\\'s tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw=) [oncologynewscentral](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW). This approval was based on the TRANSCEND CLL 004 trial, which demonstrated significant improvements in response rates and survival [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==0) [ajmc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOFkLkSvvn7iN6oLkkJmO73AF3fIdB5ypBGSMAzyojkSOdN-ZJdZADQZSgtQmpq3L9bj5efL1XvjkI4_aEnTxfag7Hvo-nedOBQJGbpbecImybmKSflOlDy6xvMqhpHFFdb1-O7fAVT2rPF75JVJFwzz-U3WcocL14xwdu8krZGWoZMbd6uWVzlJGYoL4WH5r1YO85WAFfNP3V4QU0mOSVDHY=).\\n*   **Non-Covalent BTK Inhibitors**: Pirtobrutinib (Jaypirca) is a non-covalent (reversible) BTK inhibitor that has received regulatory approval. It is effective in heavily pretreated patients, including those whose disease has progressed on covalent BTK inhibitors (like ibrutinib, acalabrutinib, or zanubrutinib) and BCL-2 inhibitors [bloodcancerstoday](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw==0). The phase 3 BRUIN CLL-321 trial showed that pirtobrutinib improved progression-free survival compared to standard chemoimmunotherapy or idelalisib-based regimens [ascopubs](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1iFL5oo39UiFgsaSNBtPdJApLTVrb4Q2kOB6POyY5VeAhX0Rbh92Tswf3yjVLjDt7ahyJPT65vVV7ml1fTsAt2qL8yTbasOj_NVa56fPRK23KjXucwLoaEXgmVQltc17caiLb30nWJvFGsRBjqU1ls0dcvVMAozmsebHfof55sviqmw2JDCrWh0s7CXcANZAp4p3PtkRSI0Iu3KHB-EXhMbZoo6r5k8UgOARk7akGAQ==).\\n*   **Next-Generation Covalent BTK Inhibitors**: Zanubrutinib (Brukinsa) is approved for both newly diagnosed and R/R CLL/SLL [lls](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk=). It has shown a better response rate and improved tolerability compared to the first-generation BTK inhibitor, ibrutinib [cancer](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk=) [lls](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk=). Other approved covalent BTK inhibitors include acalabrutinib and ibrutinib [cancer](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk=).\\n*   **BCL-2 Inhibitors**: Venetoclax is a key BCL-2 inhibitor used in treating R/R CLL/SLL, often in combination with a CD20 monoclonal antibody [mdpi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWFaKT_dXLe_ku-nu2OwFKkht3MJ4DW9u0JQEK9SwUT2hT03959Mrya76hkd5sFE8akKGtj8gQNtdqzAvpP7CcLDj1-kc_K_qkbfoE45xtXuNSKpSRV99XYdknW6CjwMV5) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI=).\\n\\n### **Ongoing Research and Clinical Trials**\\n\\nActive clinical trials are exploring the next wave of therapies aimed at overcoming resistance and further improving patient outcomes.\\n\\n*   **BTK Degraders**: This new class of drugs aims to completely eliminate the BTK protein, offering a potential solution for resistance to BTK inhibitors [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g). NX-5948 is a promising BTK degrader that has received FDA Fast Track designation for heavily pretreated R/R CLL/SLL patients, with pivotal studies planned for 2025 [nurixtx](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-JgsLVY6qxEpKoizDonaGVNgbnxNkBmWCY0tCwDksYpf9LOWh9wDeiRzHW3IwFOMRLnaWZML8pAnnF0SPllvM1mh8epO19PmQ14ng0UwTs-oT-RsXR7koSJqvcBYYbptmUUarE5Nq6YyZGSDG5t7Uq_kwEOaA9y4g8V072fkd4fPdusFAikHeNjHxu-XJTX1sJuqijMoeUCMBY3220ehVm2ohOTT3UXlGDw==). Other degraders in trials include NX-2127 and BGB-16673 [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g).\\n*   **Novel BCL-2 Inhibitors**: Sonrotoclax is a next-generation BCL-2 inhibitor showing high efficacy. In combination with zanubrutinib, it has demonstrated a 97% overall response rate in R/R CLL/SLL [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg==). Updated data shows a 30-month progression-free survival rate of 94.7% in a high-risk patient group, with encouraging safety [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOaWY1mtM3ecBCUSnypB05vs3dJ8zBbepgvL_cI7wxSydlKw0ICG1QmzWhrm7dXCUBb0NtQhhT1EZLE_ZpbHQmYTjZicEYa551y-iQI0Y4sHVWQQN8_MNwfcaxXdhDWf9dZo5yHw==).\\n*   **Advanced CAR T-Cell Therapies**: Research continues to refine CAR T-cell therapy. A phase 1b trial is evaluating an allogeneic (\"off-the-shelf\") CAR T-cell therapy, azercabtagene zapreleucel (azer-cel), in CLL/SLL patients [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==1).\\n*   **Combination Therapies**: Numerous trials are testing novel combinations. One trial is assessing the safety of RP-3500 plus olaparib in R/R CLL patients with high-risk genetic mutations [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==2). Another study found that combining the bispecific antibody epcoritamab with venetoclax resulted in superior killing of CLL cells compared to either drug alone [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==3).\\n\\n### **Strategies to Overcome Treatment Resistance**\\n\\nAs targeted therapies become standard, understanding and overcoming resistance is a major focus of research.\\n\\n*   **Resistance to BTK Inhibitors**: Covalent BTK inhibitors like ibrutinib and zanubrutinib can be rendered ineffective by a C481S mutation in the BTK protein [ashpublications](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc=). Non-covalent inhibitors like pirtobrutinib can overcome this specific mutation but may be susceptible to other, less common BTK mutations [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=). BTK degraders are being developed to destroy the BTK protein entirely, bypassing these mutation-based resistance mechanisms [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g).\\n*   **Resistance to BCL-2 Inhibitors**: Resistance to venetoclax is often driven by a G101V mutation in the BCL2 protein [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g=). Novel BCL-2 inhibitors like sonrotoclax are designed with a different binding mechanism that maintains potency against this mutation [bloodcancerstoday](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g=).\\n*   **Resistance to CAR T-Cell Therapy**: Resistance to CAR T-cells can occur through several mechanisms, including the cancer cells losing the target antigen (antigen escape), CAR T-cell exhaustion, or suppression by the tumor microenvironment [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=3) [researchgate](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=2). Strategies to combat this include developing \"armored\" CAR T-cells that are more resilient, creating CAR T-cells that target multiple antigens, and combining CAR T-cell therapy with other drugs to boost their function and persistence [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=4) [mdpi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=6).\\n\\nGiven the rapid pace of development, participation in clinical trials remains a crucial option for patients with R/R CLL/SLL, offering access to the next generation of therapies [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw==1). Patients are encouraged to discuss these ongoing treatment options and clinical trials with a CLL specialist [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMVUS8lGgTxBgiqGz0YuVZDW51UIjKC3sUJP2qptikwwQ5YJ3-7lT_qSJJv1RCH1qwbysN1xeIoOpMKOC69rsBnHhXuxagEBB59veyAlrZhWI9VKBLLjUfo2ePTy8vokAdqVuStrBi4qZwtg42z5L96JENJvwGDww=) [lymphoma](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E=).', additional_kwargs={}, response_metadata={}, id='43b82229-0794-48e1-bc5b-877dbfe10eef')],\n",
       " 'search_query': ['ongoing clinical trials relapsed refractory CLL SLL',\n",
       "  'FDA approved therapies relapsed refractory CLL SLL July 2025',\n",
       "  'ongoing clinical trials relapsed refractory CLL SLL',\n",
       "  'FDA approved therapies relapsed refractory CLL SLL July 2025',\n",
       "  'What are the specific resistance mechanisms identified for next-generation BTK inhibitors, BTK degraders, novel BCL-2 inhibitors (e.g., sonrotoclax), and CAR T-cell therapies (e.g., liso-cel) in relapsed/refractory CLL/SLL, and what are the current research strategies or clinical trial approaches being explored to overcome these resistances?'],\n",
       " 'web_research_result': ['Okay, I will conduct Google Searches to gather the most recent, credible information on \"ongoing clinical trials relapsed refractory CLL SLL\" and synthesize it into a verifiable text artifact.\\nOngoing clinical trials for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are exploring new therapies and combinations, reflecting significant advancements in the treatment landscape [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0) [ajmc](https://vertexaisearch.cloud.google.com/id/0-1).\\n\\n**Key areas of investigation:**\\n\\n*   **BTK Inhibitors and Degraders:**\\n    *   Next-generation Bruton\\'s tyrosine kinase (BTK) inhibitors like acalabrutinib and zanubrutinib are recommended over ibrutinib for relapsed/refractory CLL/SLL, based on improved tolerability and efficacy [ashpublications](https://vertexaisearch.cloud.google.com/id/0-2).\\n    *   BTK degraders, such as NX-5948, are showing promise in heavily pre-treated patients with poor prognoses [cllsociety](https://vertexaisearch.cloud.google.com/id/0-3) [cllsociety](https://vertexaisearch.cloud.google.com/id/0-4). Nurix Therapeutics is planning pivotal studies for NX-5948 in 2025 [nurixtx](https://vertexaisearch.cloud.google.com/id/0-5). NX-5948 has received Fast Track designation from the FDA for r/r CLL/SLL after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor [nurixtx](https://vertexaisearch.cloud.google.com/id/0-5).\\n    *   The phase 3 BRUIN CLL-321 trial demonstrated that pirtobrutinib, a non-covalent BTK inhibitor, improves progression-free survival (PFS) and time to next treatment compared to idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed or refractory CLL and SLL [ascopubs](https://vertexaisearch.cloud.google.com/id/0-6). Pirtobrutinib may become a commonly utilized control arm in relapsed/refractory CLL [ascopubs](https://vertexaisearch.cloud.google.com/id/0-6).\\n*   **BCL-2 Inhibitors:**\\n    *   Sonrotoclax, a novel BCL2 inhibitor, combined with the BTK inhibitor zanubrutinib, has shown an overall response rate of 97% in relapsed CLL/SLL [cllsociety](https://vertexaisearch.cloud.google.com/id/0-4). Updated Phase I results of sonrotoclax plus zanubrutinib show encouraging safety and efficacy, with a 30-month progression-free survival (PFS) rate of 94.7% in a patient population enriched for high-risk characteristics [youtube](https://vertexaisearch.cloud.google.com/id/0-7).\\n    *   Venetoclax, combined with a CD20 monoclonal antibody, has demonstrated excellent activity in treating both previously untreated and relapsed/refractory CLL/SLL [mdpi](https://vertexaisearch.cloud.google.com/id/0-8).\\n*   **CAR T-cell Therapy:**\\n    *   Lisocabtagene maraleucel (liso-cel; Breyanzi) is approved by the FDA for third-line or later treatment of patients with CLL/SLL who have received prior BTK and BCL2 inhibitors [ajmc](https://vertexaisearch.cloud.google.com/id/0-9) [targetedonc](https://vertexaisearch.cloud.google.com/id/0-10) [mdpi](https://vertexaisearch.cloud.google.com/id/0-8). The TRANSCEND CLL 004 trial supported this approval [targetedonc](https://vertexaisearch.cloud.google.com/id/0-10).\\n    *   Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments [ajmc](https://vertexaisearch.cloud.google.com/id/0-9).\\n    *   Research is ongoing with other novel therapies like BTK degraders, bispecific antibodies, and other CAR T-cell targets for patients who have failed both BTK inhibitors and venetoclax [targetedonc](https://vertexaisearch.cloud.google.com/id/0-10).\\n    *   A phase 1b trial of azercabtagene zapreleucel (azer-cel), an allogeneic CAR T-cell therapy, is showing promising activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and has expanded to include CLL/SLL [targetedonc](https://vertexaisearch.cloud.google.com/id/0-11).\\n*   **Combination Therapies:**\\n    *   A phase 1 clinical trial is recruiting patients with relapsed/refractory CLL to test the safety of a combination of RP-3500 and olaparib, particularly for those with high-risk genetic alterations [cllsociety](https://vertexaisearch.cloud.google.com/id/0-12).\\n    *   Combining epcoritamab with venetoclax induced superior killing of CLL cells compared to either agent alone [nih](https://vertexaisearch.cloud.google.com/id/0-13).\\n*   **Other Targeted Therapies and Approaches:**\\n    *   Clinical trials are evaluating multi-specific antibodies for CLL and/or SLL [nih](https://vertexaisearch.cloud.google.com/id/0-13).\\n    *   Treatment approaches are increasingly tailored based on specific markers and mutations identified in cancer cells [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0).\\n\\n**Key Considerations in Treatment Selection:**\\n\\n*   Prior therapies and duration of remission [nih](https://vertexaisearch.cloud.google.com/id/0-14) [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0).\\n*   Prognostic features of the disease [nih](https://vertexaisearch.cloud.google.com/id/0-14) [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0).\\n*   Patient\\'s health and comorbidities [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0) [ashpublications](https://vertexaisearch.cloud.google.com/id/0-2).\\n*   Specific markers and mutations [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0).\\n\\nIt\\'s important to note that clinical trials are continuously evolving, and patients are encouraged to discuss available options with their physicians and seek out specialized CLL experts [cllsociety](https://vertexaisearch.cloud.google.com/id/0-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/0-10) [cllsociety](https://vertexaisearch.cloud.google.com/id/0-4) [lymphoma](https://vertexaisearch.cloud.google.com/id/0-0).\\n',\n",
       "  'Okay, I will conduct Google Searches to gather the most recent and credible information on \"FDA approved therapies for relapsed/refractory CLL/SLL as of July 2025\" and synthesize it into a verifiable text artifact.\\n\\nAs of July 2025, treatment options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to evolve, with a focus on targeted therapies and novel agents [nih](https://vertexaisearch.cloud.google.com/id/1-0) [targetedonc](https://vertexaisearch.cloud.google.com/id/1-1) [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2).\\n\\n**FDA-Approved Therapies:**\\n\\n*   **Lisocabtagene maraleucel (liso-cel; Breyanzi):** The FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor [targetedonc](https://vertexaisearch.cloud.google.com/id/1-3) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/1-4) [curetoday](https://vertexaisearch.cloud.google.com/id/1-5). Liso-cel is the first CAR T-cell therapy to receive approval for CLL/SLL [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/1-4) [targetedonc](https://vertexaisearch.cloud.google.com/id/1-3). The approval was based on the TRANSCEND CLL 004 trial [targetedonc](https://vertexaisearch.cloud.google.com/id/1-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/1-6) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Zanubrutinib (Brukinsa):** Zanubrutinib, a next-generation BTK inhibitor, is approved for CLL/SLL [cancer](https://vertexaisearch.cloud.google.com/id/1-7) [lls](https://vertexaisearch.cloud.google.com/id/1-8). It is approved for both first-line and relapsed/refractory CLL/SLL [lls](https://vertexaisearch.cloud.google.com/id/1-8). Clinical trials have demonstrated that zanubrutinib has a better overall response rate and is easier to tolerate than ibrutinib [lls](https://vertexaisearch.cloud.google.com/id/1-8) [cancer](https://vertexaisearch.cloud.google.com/id/1-7). Brukinsa is also available in a new tablet form, reducing the number of daily pills from 4 to 2 [curetoday](https://vertexaisearch.cloud.google.com/id/1-5) [stocktitan](https://vertexaisearch.cloud.google.com/id/1-9).\\n*   **Pirtobrutinib (Jaypirca):** Pirtobrutinib, a noncovalent BTK inhibitor, has received regulatory approval [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2) [nih](https://vertexaisearch.cloud.google.com/id/1-10). It has demonstrated prolonged progression-free survival in heavily pretreated patients, including those who are double refractory to BTK and BCL-2 inhibitors [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2).\\n\\n**Other Treatment Options and Considerations:**\\n\\n*   **BTK Inhibitors:** Ibrutinib, acalabrutinib and zanubrutinib are approved BTK inhibitors used in CLL/SLL [cancer](https://vertexaisearch.cloud.google.com/id/1-7) [nih](https://vertexaisearch.cloud.google.com/id/1-0).\\n*   **BCL-2 Inhibitors:** Venetoclax is an example of BCL-2 inhibitor used in CLL/SLL [nih](https://vertexaisearch.cloud.google.com/id/1-0).\\n*   **Combination Therapies:** Clinical trials have explored combinations of BTK inhibitors and venetoclax, which have led to complete responses in some patients [lls](https://vertexaisearch.cloud.google.com/id/1-8).\\n*   **Clinical Trials:** Participation in clinical trials is considered a good option, especially for R/R CLL/SLL, as it provides access to experimental therapies [cllsociety](https://vertexaisearch.cloud.google.com/id/1-11). Novel agents in development include BTK degraders and bispecific antibodies [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2) [nih](https://vertexaisearch.cloud.google.com/id/1-10).\\n*   **Treatment Sequencing:** Many patients with CLL are treated sequentially with covalent BTK inhibitors and the BCL2 inhibitor venetoclax as their first- and second-line therapies [nih](https://vertexaisearch.cloud.google.com/id/1-10).\\n\\n**Important Considerations:**\\n\\n*   **Minimal Residual Disease (MRD):** Achieving undetectable MRD has been associated with ibrutinib and venetoclax [nih](https://vertexaisearch.cloud.google.com/id/1-0) [targetedonc](https://vertexaisearch.cloud.google.com/id/1-3).\\n*   **Tolerability:** Tolerability is a significant concern in later lines of therapy [targetedonc](https://vertexaisearch.cloud.google.com/id/1-1).\\n*   **Diminishing Outcomes:** Real-world data indicates that outcomes decline with each additional line of treatment [targetedonc](https://vertexaisearch.cloud.google.com/id/1-1).\\n*   **Individualized Treatment:** Treatment decisions should be individualized based on patient-specific factors, including genomic features and prior therapies [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2) [nih](https://vertexaisearch.cloud.google.com/id/1-10).\\n\\n**Ongoing Research:**\\n\\n*   Research is ongoing to develop novel therapies, such as BTK degraders and bispecific antibodies [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2) [targetedonc](https://vertexaisearch.cloud.google.com/id/1-6) [nih](https://vertexaisearch.cloud.google.com/id/1-10).\\n*   CAR T-cell therapy is being explored in combination with other agents [cllsociety](https://vertexaisearch.cloud.google.com/id/1-11).\\n*   Studies are evaluating strategies to improve the durability of responses and overcome resistance to existing therapies [nih](https://vertexaisearch.cloud.google.com/id/1-10) [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/1-2).\\n',\n",
       "  'Okay, I will conduct Google Searches to gather the most recent information on resistance mechanisms and strategies to overcome them for next-generation BTK inhibitors, BTK degraders, novel BCL-2 inhibitors (e.g., sonrotoclax), and CAR T-cell therapies (e.g., liso-cel) in relapsed/refractory CLL/SLL. Then I will synthesize the information into a verifiable text artifact.\\nHere\\'s a summary of the resistance mechanisms and research strategies for next-generation BTK inhibitors, BTK degraders, novel BCL-2 inhibitors (e.g., sonrotoclax), and CAR T-cell therapies (e.g., liso-cel) in relapsed/refractory CLL/SLL:\\n\\n**Next-Generation BTK Inhibitors**\\n\\n*   **Resistance Mechanisms:**\\n    *   The first-generation BTK inhibitor ibrutinib and the second-generation BTK inhibitors acalabrutinib and zanubrutinib, which are covalent BTKis, bind to BTK C481 and are all susceptible to the C481S mutation [ashpublications](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1).\\n    *   Noncovalent BTK inhibitors like pirtobrutinib can overcome C481S resistance but are associated with other variant (non-C481) BTK mutations, including those associated with resistance to acalabrutinib and zanubrutinib (T474 codon and L528W mutations) [ashpublications](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1).\\n*   **Strategies to Overcome Resistance:**\\n    *   BTK degraders are being studied to overcome resistance, as they eliminate the BTK protein entirely, including those with BTK mutations [healthtree](https://vertexaisearch.cloud.google.com/id/4-2) [cllsociety](https://vertexaisearch.cloud.google.com/id/4-3).\\n    *   Combining BTK inhibitors with venetoclax in limited-duration regimens may prevent or delay the emergence of BTK mutations [ashpublications](https://vertexaisearch.cloud.google.com/id/4-0).\\n    *   Non-covalent BTK inhibitors, such as pirtobrutinib, bind to BTK in a different way and can work in patients who progress on covalent BTK inhibitors [patientpower](https://vertexaisearch.cloud.google.com/id/4-4).\\n\\n**BTK Degraders**\\n\\n*   **Resistance Mechanisms:**\\n    *   A recent report detected A428D in a patient who developed clinical resistance to a BTK degrader, but this requires functional validation [ashpublications](https://vertexaisearch.cloud.google.com/id/4-0).\\n*   **Strategies to Overcome Resistance:**\\n    *   BTK degraders are designed to completely eliminate the BTK protein, which can halt the growth of CLL cells, including those resistant to BTK inhibitors caused by BTK mutations [healthtree](https://vertexaisearch.cloud.google.com/id/4-2).\\n    *   Examples of BTK degraders in early-phase clinical trials include NX-2127, NX-5948, and BGB-16673 [healthtree](https://vertexaisearch.cloud.google.com/id/4-2).\\n    *   Dr. Quinlan Sievers is researching how and why resistance to BTK degraders develops, using genetic sequencing and laboratory models to identify resistance pathways [prnewswire](https://vertexaisearch.cloud.google.com/id/4-5).\\n    *   BGB-16673 is designed to induce degradation of wild-type and multiple mutant forms of BTK, including those that commonly confer resistance to BTK inhibitors [targetedonc](https://vertexaisearch.cloud.google.com/id/4-6).\\n    *   NX-2127 has been shown to enhance the function of patients\\' cancer-fighting T-cells, helping to reverse the immune suppression commonly seen in individuals with CLL [healthtree](https://vertexaisearch.cloud.google.com/id/4-2).\\n    *   AC676 is a chimeric degrader that uses a proprietary Protein-Protein Interaction Targeting Chimeras (PPI-TAC) platform to induce ubiquitination and degradation of BTK [targetedonc](https://vertexaisearch.cloud.google.com/id/4-6).\\n\\n**Novel BCL-2 Inhibitors (e.g., Sonrotoclax)**\\n\\n*   **Resistance Mechanisms:**\\n    *   Resistance to venetoclax, a BCL2 inhibitor, is often driven by the G101V mutation in BCL2 [nih](https://vertexaisearch.cloud.google.com/id/4-7) [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/4-8) [nih](https://vertexaisearch.cloud.google.com/id/4-9).\\n*   **Strategies to Overcome Resistance:**\\n    *   Sonrotoclax, a next-generation selective BCL2 inhibitor, demonstrates stronger cytotoxic activity and more profound tumor growth inhibition compared with venetoclax in preclinical models [nih](https://vertexaisearch.cloud.google.com/id/4-9) [nih](https://vertexaisearch.cloud.google.com/id/4-7) [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/4-8).\\n    *   Sonrotoclax adopts a novel binding mode within the P2 pocket of BCL2, which could explain why it maintains stronger potency than venetoclax against the G101V mutation [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/4-8) [nih](https://vertexaisearch.cloud.google.com/id/4-7).\\n    *   Sonrotoclax is under investigation in clinical trials [nih](https://vertexaisearch.cloud.google.com/id/4-9) [bloodcancerstoday](https://vertexaisearch.cloud.google.com/id/4-8) [nih](https://vertexaisearch.cloud.google.com/id/4-7).\\n    *   Combining sonrotoclax with zanubrutinib, a BTK inhibitor, has shown promising results in treatment-na√Øve CLL patients. [cllsociety](https://vertexaisearch.cloud.google.com/id/4-10) [healthtree](https://vertexaisearch.cloud.google.com/id/4-11)\\n\\n**CAR T-Cell Therapies (e.g., Liso-cel)**\\n\\n*   **Resistance Mechanisms:**\\n    *   Tumor-related factors such as antigen escape (proliferation of antigen-negative clones, mutations within the antigen gene locus, loss of heterogeneity, alternative splicing, lineage switching, trogocytosis). [researchgate](https://vertexaisearch.cloud.google.com/id/4-12) [nih](https://vertexaisearch.cloud.google.com/id/4-13)\\n    *   CAR T-cell-intrinsic factors such as T-cell exhaustion (expression of PD-1, LAG-3), leading to impaired expansion, cytotoxicity, and persistence. [nih](https://vertexaisearch.cloud.google.com/id/4-13) [researchgate](https://vertexaisearch.cloud.google.com/id/4-12)\\n    *   A suppressive tumor microenvironment (TME) with immunosuppressive cells, inhibitory cytokines, and vesicles that protect CLL cells and cause impaired CAR T-cell function. [researchgate](https://vertexaisearch.cloud.google.com/id/4-12) [nih](https://vertexaisearch.cloud.google.com/id/4-13)\\n*   **Strategies to Overcome Resistance:**\\n    *   Concurrent administration of therapies that augment CAR T-cell endurance and function. [nih](https://vertexaisearch.cloud.google.com/id/4-14) [nih](https://vertexaisearch.cloud.google.com/id/4-13)\\n    *   Engineering of novel CAR T-cells targeting different antigens. [nih](https://vertexaisearch.cloud.google.com/id/4-14) [nih](https://vertexaisearch.cloud.google.com/id/4-13)\\n    *   \"Armored\" CAR T-cells, armed with transgenic modulators to modify both CAR T-cell function and the tumor milieu. [nih](https://vertexaisearch.cloud.google.com/id/4-14) [researchgate](https://vertexaisearch.cloud.google.com/id/4-12)\\n    *   Development of readily available, allogeneic CAR T-cells and natural killer (NK) cells to counteract innate T-cell defects in CLL patients. [researchgate](https://vertexaisearch.cloud.google.com/id/4-12) [nih](https://vertexaisearch.cloud.google.com/id/4-14)\\n    *   Combining liso-cel with ibrutinib has shown promising results in relapsed CLL/SLL. [nih](https://vertexaisearch.cloud.google.com/id/4-15) [cllsociety](https://vertexaisearch.cloud.google.com/id/4-3)\\n    *   Bispecific CAR T-cells have been developed to reduce the risk of CD19 antigen escape. [mdpi](https://vertexaisearch.cloud.google.com/id/4-16)\\n    *   Strategies that target BCMA may improve outcomes for patients with CLL. [mdpi](https://vertexaisearch.cloud.google.com/id/4-16)\\n    *   Lower tumor burden prior to liso-cel treatment is associated with a higher likelihood of response. [targetedonc](https://vertexaisearch.cloud.google.com/id/4-17)\\n    *   Third-generation CAR T-cell therapies aim to mitigate the exhaustion observed with second-generation options. [ajmc](https://vertexaisearch.cloud.google.com/id/4-18)\\n\\n**General Strategies and Considerations**\\n\\n*   **Combination Therapies:** Combining targeted therapies with different mechanisms of action is a key strategy to overcome resistance. [iwmf](https://vertexaisearch.cloud.google.com/id/4-19) [nih](https://vertexaisearch.cloud.google.com/id/4-15) [cllsociety](https://vertexaisearch.cloud.google.com/id/4-20)\\n*   **Monitoring and Personalized Treatment:** Understanding resistance mechanisms can inform a personalized approach to treatment. [nih](https://vertexaisearch.cloud.google.com/id/4-15) [mdpi](https://vertexaisearch.cloud.google.com/id/4-21)\\n*   **Clinical Trials:** Ongoing clinical trials are exploring novel treatment options for double-refractory CLL, including bispecific antibodies, second-generation BCL2 inhibitors, additional non-covalent BTK inhibitors, and BTK degraders. [nih](https://vertexaisearch.cloud.google.com/id/4-15)\\n*   **Early Intervention:** Earlier use of CAR T-cell therapy may improve responses. [cancernetwork](https://vertexaisearch.cloud.google.com/id/4-22)\\n'],\n",
       " 'sources_gathered': [{'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ=='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvlulmhICi4tvjVdn_CMcyXCeGS053wlP4ZH-9A9KLHlQxU-9upDtIEd_Lqtxwc3UVpnrGlqRfImLLsS9jfpjo6BpvzBV6_W611gPVAgCNi7OZ08zxBiO0SszEyFEBbhyrg9bXd04rw8DcevaO-vPZxk19XzwPVrl4JPPtCJXX8lFx5K6burDRu9gK_dHR-hNF1AACcQix3PkThtHRmvfsuc1AdQgQDnOfAmc9'},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMVUS8lGgTxBgiqGz0YuVZDW51UIjKC3sUJP2qptikwwQ5YJ3-7lT_qSJJv1RCH1qwbysN1xeIoOpMKOC69rsBnHhXuxagEBB59veyAlrZhWI9VKBLLjUfo2ePTy8vokAdqVuStrBi4qZwtg42z5L96JENJvwGDww='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg=='},\n",
       "  {'label': 'nurixtx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-JgsLVY6qxEpKoizDonaGVNgbnxNkBmWCY0tCwDksYpf9LOWh9wDeiRzHW3IwFOMRLnaWZML8pAnnF0SPllvM1mh8epO19PmQ14ng0UwTs-oT-RsXR7koSJqvcBYYbptmUUarE5Nq6YyZGSDG5t7Uq_kwEOaA9y4g8V072fkd4fPdusFAikHeNjHxu-XJTX1sJuqijMoeUCMBY3220ehVm2ohOTT3UXlGDw=='},\n",
       "  {'label': 'nurixtx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-JgsLVY6qxEpKoizDonaGVNgbnxNkBmWCY0tCwDksYpf9LOWh9wDeiRzHW3IwFOMRLnaWZML8pAnnF0SPllvM1mh8epO19PmQ14ng0UwTs-oT-RsXR7koSJqvcBYYbptmUUarE5Nq6YyZGSDG5t7Uq_kwEOaA9y4g8V072fkd4fPdusFAikHeNjHxu-XJTX1sJuqijMoeUCMBY3220ehVm2ohOTT3UXlGDw=='},\n",
       "  {'label': 'ascopubs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1iFL5oo39UiFgsaSNBtPdJApLTVrb4Q2kOB6POyY5VeAhX0Rbh92Tswf3yjVLjDt7ahyJPT65vVV7ml1fTsAt2qL8yTbasOj_NVa56fPRK23KjXucwLoaEXgmVQltc17caiLb30nWJvFGsRBjqU1ls0dcvVMAozmsebHfof55sviqmw2JDCrWh0s7CXcANZAp4p3PtkRSI0Iu3KHB-EXhMbZoo6r5k8UgOARk7akGAQ=='},\n",
       "  {'label': 'ascopubs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1iFL5oo39UiFgsaSNBtPdJApLTVrb4Q2kOB6POyY5VeAhX0Rbh92Tswf3yjVLjDt7ahyJPT65vVV7ml1fTsAt2qL8yTbasOj_NVa56fPRK23KjXucwLoaEXgmVQltc17caiLb30nWJvFGsRBjqU1ls0dcvVMAozmsebHfof55sviqmw2JDCrWh0s7CXcANZAp4p3PtkRSI0Iu3KHB-EXhMbZoo6r5k8UgOARk7akGAQ=='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOaWY1mtM3ecBCUSnypB05vs3dJ8zBbepgvL_cI7wxSydlKw0ICG1QmzWhrm7dXCUBb0NtQhhT1EZLE_ZpbHQmYTjZicEYa551y-iQI0Y4sHVWQQN8_MNwfcaxXdhDWf9dZo5yHw=='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWFaKT_dXLe_ku-nu2OwFKkht3MJ4DW9u0JQEK9SwUT2hT03959Mrya76hkd5sFE8akKGtj8gQNtdqzAvpP7CcLDj1-kc_K_qkbfoE45xtXuNSKpSRV99XYdknW6CjwMV5'},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOFkLkSvvn7iN6oLkkJmO73AF3fIdB5ypBGSMAzyojkSOdN-ZJdZADQZSgtQmpq3L9bj5efL1XvjkI4_aEnTxfag7Hvo-nedOBQJGbpbecImybmKSflOlDy6xvMqhpHFFdb1-O7fAVT2rPF75JVJFwzz-U3WcocL14xwdu8krZGWoZMbd6uWVzlJGYoL4WH5r1YO85WAFfNP3V4QU0mOSVDHY='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeapM73otZKInnPOuYrrgcbSFRA68Nhhi6VM7uxaLlViKZb_eZaP400-sU3_TgYvrkRDSVRjwgPk8irN2pkZzLI4YU1FGpDJyusuZzfHwRzpR0IZbPnKGlweb5MTbtZ14UGpKMT9-kbq3vP9MG_wseNwNLgb6fS0Jf-4BnCJxDPGmBp5ZDjOtMsiAg-YvFWwqJesHLOf74fFQHObDf3g=='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWFaKT_dXLe_ku-nu2OwFKkht3MJ4DW9u0JQEK9SwUT2hT03959Mrya76hkd5sFE8akKGtj8gQNtdqzAvpP7CcLDj1-kc_K_qkbfoE45xtXuNSKpSRV99XYdknW6CjwMV5'},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeapM73otZKInnPOuYrrgcbSFRA68Nhhi6VM7uxaLlViKZb_eZaP400-sU3_TgYvrkRDSVRjwgPk8irN2pkZzLI4YU1FGpDJyusuZzfHwRzpR0IZbPnKGlweb5MTbtZ14UGpKMT9-kbq3vP9MG_wseNwNLgb6fS0Jf-4BnCJxDPGmBp5ZDjOtMsiAg-YvFWwqJesHLOf74fFQHObDf3g=='},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOFkLkSvvn7iN6oLkkJmO73AF3fIdB5ypBGSMAzyojkSOdN-ZJdZADQZSgtQmpq3L9bj5efL1XvjkI4_aEnTxfag7Hvo-nedOBQJGbpbecImybmKSflOlDy6xvMqhpHFFdb1-O7fAVT2rPF75JVJFwzz-U3WcocL14xwdu8krZGWoZMbd6uWVzlJGYoL4WH5r1YO85WAFfNP3V4QU0mOSVDHY='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeapM73otZKInnPOuYrrgcbSFRA68Nhhi6VM7uxaLlViKZb_eZaP400-sU3_TgYvrkRDSVRjwgPk8irN2pkZzLI4YU1FGpDJyusuZzfHwRzpR0IZbPnKGlweb5MTbtZ14UGpKMT9-kbq3vP9MG_wseNwNLgb6fS0Jf-4BnCJxDPGmBp5ZDjOtMsiAg-YvFWwqJesHLOf74fFQHObDf3g=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFooAaAmx4YKQJW7KLBGHKq0-1P6XRGWhx_v0G3HOiE61kl2BO2ywCFDz8rDbq_hRiO_sWipqplx9mT09CK_FEUvHuE25AUOCRNJY_QCZw89416IgaL2hYmbHfeP12H1uU6FRT0LLGWNigVR9ltAfl94i6KGWINmlkFpKaVoyVNQoQIWtADV0TC9fWVgDhMzWromm8uT-wOqdH6E_f78GP-uvtkVg=='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEB4ZPcgYI9Zl2wrG8opj5ibFyxWik1rMWvNT2zXoUAGDkqbzFFPbEAgZ5TNLkAjk_ITXKMqPFA4azphDJNKtD1SIk4qU4G8UGS1P5-1bRYT9N3aeQX10wcpD_rTmMTfLgKKjo68EeALQQ4h56E6h6nH90ovbb-H-IJIJouCaezfR4-AN30mtOF6GFm-Ua3a1w3Qnx4wQ=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiowi3BWdOKc-oF-R-bpnBduLSwYjgeQYMWlTM92nccZMD782dfRPT7i_WPRmytx5xUPU5zbXz3I97atdANy7LCXJaLmpDdJHdZCC5vbM1jOFukdGHa26ELgIUjzm8fGsxQo7zWag_egsRbac='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiowi3BWdOKc-oF-R-bpnBduLSwYjgeQYMWlTM92nccZMD782dfRPT7i_WPRmytx5xUPU5zbXz3I97atdANy7LCXJaLmpDdJHdZCC5vbM1jOFukdGHa26ELgIUjzm8fGsxQo7zWag_egsRbac='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1s7EtuRHHEauEHU9Rxgs6tE6XJ_FmMnJXCslXZW-3foc3kjF1w4FM0txabjb7v7eq1_lYpwWIe79AxwBtTbSxPu6zvFpCs60T-4M4BL9VMXHl8o29k6Ro9pqswq7mWBLpLPNvaQycw2jpiA=='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1s7EtuRHHEauEHU9Rxgs6tE6XJ_FmMnJXCslXZW-3foc3kjF1w4FM0txabjb7v7eq1_lYpwWIe79AxwBtTbSxPu6zvFpCs60T-4M4BL9VMXHl8o29k6Ro9pqswq7mWBLpLPNvaQycw2jpiA=='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvlulmhICi4tvjVdn_CMcyXCeGS053wlP4ZH-9A9KLHlQxU-9upDtIEd_Lqtxwc3UVpnrGlqRfImLLsS9jfpjo6BpvzBV6_W611gPVAgCNi7OZ08zxBiO0SszEyFEBbhyrg9bXd04rw8DcevaO-vPZxk19XzwPVrl4JPPtCJXX8lFx5K6burDRu9gK_dHR-hNF1AACcQix3PkThtHRmvfsuc1AdQgQDnOfAmc9'},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMVUS8lGgTxBgiqGz0YuVZDW51UIjKC3sUJP2qptikwwQ5YJ3-7lT_qSJJv1RCH1qwbysN1xeIoOpMKOC69rsBnHhXuxagEBB59veyAlrZhWI9VKBLLjUfo2ePTy8vokAdqVuStrBi4qZwtg42z5L96JENJvwGDww='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeapM73otZKInnPOuYrrgcbSFRA68Nhhi6VM7uxaLlViKZb_eZaP400-sU3_TgYvrkRDSVRjwgPk8irN2pkZzLI4YU1FGpDJyusuZzfHwRzpR0IZbPnKGlweb5MTbtZ14UGpKMT9-kbq3vP9MG_wseNwNLgb6fS0Jf-4BnCJxDPGmBp5ZDjOtMsiAg-YvFWwqJesHLOf74fFQHObDf3g=='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg=='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw=='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw='},\n",
       "  {'label': 'oncologynewscentral',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW'},\n",
       "  {'label': 'curetoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRMryb6_ohBm5GIjXh_e3l9SrJy2UG8A5O96dzV3qu_Mc4uUIuVOtn4MCBdQzsDIFnv7UDUSDJDSRBpV690LmgnsX5N6hQvcpaZo3IfHJ9UjSeaDFx6iV6mA3VtcErHnfhqe5dQLgGeCe4JJXeRufL4ACZvJ8OukE7dmQqZwXfWrWFDfCVjYcfsPrGg3Qs8Q=='},\n",
       "  {'label': 'oncologynewscentral',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW'},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfnQ0wn-MhiT0tEEi8F3qwibL5hB7KMLo83-_j9mXdezdLWlOwAFALPbKfNdNMnlant7FUOzAcf2FJk4brwBMswAAV-rjYS9RAqwCfaVfqbB2NcfMl256VxTn-H_31S0Zm2JojR2-Sybb7P8HPgl1EH1nrqUYGY94vv5aISuvKYqT2hKfgq2zkXv4F6TdjQ4pZI6K_APXJiG9ixDOnuA8='},\n",
       "  {'label': 'oncologynewscentral',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW'},\n",
       "  {'label': 'cancer',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk='},\n",
       "  {'label': 'lls',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk='},\n",
       "  {'label': 'lls',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk='},\n",
       "  {'label': 'lls',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk='},\n",
       "  {'label': 'cancer',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk='},\n",
       "  {'label': 'curetoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRMryb6_ohBm5GIjXh_e3l9SrJy2UG8A5O96dzV3qu_Mc4uUIuVOtn4MCBdQzsDIFnv7UDUSDJDSRBpV690LmgnsX5N6hQvcpaZo3IfHJ9UjSeaDFx6iV6mA3VtcErHnfhqe5dQLgGeCe4JJXeRufL4ACZvJ8OukE7dmQqZwXfWrWFDfCVjYcfsPrGg3Qs8Q=='},\n",
       "  {'label': 'stocktitan',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiSLVSb85LYHGF5qPPHZqfAHmN73Ws6asLM74Gcqg0Y7aEPUGpCJLqeRdGjq7eRIk1S7IciYUg2Z-QEoZiiysdQ1IbRjpUbpL69U1q2lz7-IlFEatRtw9OM4qpjHtKlk20uTfEPoia4YuPtqhPFFDaGQjHcaaRIlF0jdqB5kmnrczRpC4rNkce7LJyqY9AuIpKgpK7IMC7-EyOV-XOv1Y9FUvUo0bXI3DJm6SBMTuFgdc='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'cancer',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI='},\n",
       "  {'label': 'lls',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEZ1pwRhFJFYXpC87SR7niEnVPqDCC2rAU5fWW_Z1M7dqCd5LFSlSMpkxhaUdS7V57I9BHmiUNp0sMs4yBdHyTWZhzeTA1dVrg_-wTO-JgbnXdBmwzAlwHztaxOI4GHMzJezjiIlQHJxdvZHJTTpZ9serJzLN_2S4oVMk4e-Xq0w1gflp7RmZhM4T1Y83BqcE8='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw=='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfnQ0wn-MhiT0tEEi8F3qwibL5hB7KMLo83-_j9mXdezdLWlOwAFALPbKfNdNMnlant7FUOzAcf2FJk4brwBMswAAV-rjYS9RAqwCfaVfqbB2NcfMl256VxTn-H_31S0Zm2JojR2-Sybb7P8HPgl1EH1nrqUYGY94vv5aISuvKYqT2hKfgq2zkXv4F6TdjQ4pZI6K_APXJiG9ixDOnuA8='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEZ1pwRhFJFYXpC87SR7niEnVPqDCC2rAU5fWW_Z1M7dqCd5LFSlSMpkxhaUdS7V57I9BHmiUNp0sMs4yBdHyTWZhzeTA1dVrg_-wTO-JgbnXdBmwzAlwHztaxOI4GHMzJezjiIlQHJxdvZHJTTpZ9serJzLN_2S4oVMk4e-Xq0w1gflp7RmZhM4T1Y83BqcE8='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEq_zLZypRT6Ihw0bU1GcoI8gIJwdKjt8ysgoWIoldeb1SsaIM5ul6gkqJaBnN9yRwGXJ0lOtNoqLBKSI5PDAZfPHNi_RuoTn8RQpBwe6b0MsA9Yne1JjFVptWa4Pdvgpp_Ma1k'},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ='},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g'},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPQS-7z8lisFQWsMtVGyi4lYAhRwcUq8fCbuf8CP_yjCjfHLZ0f0ATVL7Ca2wITi2UTnn9jizz1B6Z_Uv6RBXS-KWkJSscf8tLchjrJlLrOM0ik63hCDaMVlTES9f3GP6YtnpUyg3_id_eJnFfDo3h4XSvR4rTaFQ0mlZTpSXBEvtrsuJM6H0B0wP0cU1d7N6A8YpMcYs='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc='},\n",
       "  {'label': 'patientpower',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQGmRBH17WbvTSq10QJZzVPCEJxJnM_w29Rl8WTpjeL9C8hkUXaLROXwZ4XimOc_auI7E0SN8sHT2cB828MtQsQNhmEGUXU1u39sZmh-MQz3pZcC9rYdA9PNfHIPubwFteY0shfBCvz1yEQnzO-xMtSAOso_IFFoEz4Wj7V8eV-wcbMGtG88EPs6RDAAnUOHoCT0jOOx7UZDgFkw4G98TML5TdpwctVeR-'},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc='},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g'},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g'},\n",
       "  {'label': 'prnewswire',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwEw5AUgNzbbKzfnk_rK7lLW8K_9O0sjkefvfZujDVAiDdTHlduCOFvuwcPPtZOPbUKGNve1YSypO5ulWFSvkIN6_O_dfypMp02yUqhpWDf2YzKvfRNIf1otxR6b0cKTEGx5_WDk6HEBMLjXmzmwAXODDlla0LRPCmvwqd3cqV6GvKwd9x_-DiPZ-OwSlQXjoKCsGnVeXDV43n4HD2Enhz1pK0k1fkWExWeF74'},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtUYL-OBr3ZPCSYe53CayguZOjgWixR0Bsw7WXruIa1_gejLtJCWQdaZL-A0Jq2wuyg7Twi6qVJLAYqw9EH8XGzpuJcLm7wZLHs06g7YxSEA-qvNQQTeswtjXTb3fANpyDa90qTppii3IgRbT1zZGvktdkMMvWbEZhWkCL--rJVvXo6QnwWCKX9ZlGxjsWrKhzFoI='},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g'},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtUYL-OBr3ZPCSYe53CayguZOjgWixR0Bsw7WXruIa1_gejLtJCWQdaZL-A0Jq2wuyg7Twi6qVJLAYqw9EH8XGzpuJcLm7wZLHs06g7YxSEA-qvNQQTeswtjXTb3fANpyDa90qTppii3IgRbT1zZGvktdkMMvWbEZhWkCL--rJVvXo6QnwWCKX9ZlGxjsWrKhzFoI='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHirKxihVnPLBf4yCzJiHYmdC9bi-1Utllh4f0hzVHhH6_H5nvKIes8-n4Smk9XlKro6WSdyZ_ARTZoyyH2FyutKF7_-stdl05Ux6SO5SjVWonzAimWihgoaoV85WhCzNJ6mY_CtjUL93ir6RE='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHirKxihVnPLBf4yCzJiHYmdC9bi-1Utllh4f0hzVHhH6_H5nvKIes8-n4Smk9XlKro6WSdyZ_ARTZoyyH2FyutKF7_-stdl05Ux6SO5SjVWonzAimWihgoaoV85WhCzNJ6mY_CtjUL93ir6RE='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ=='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHirKxihVnPLBf4yCzJiHYmdC9bi-1Utllh4f0hzVHhH6_H5nvKIes8-n4Smk9XlKro6WSdyZ_ARTZoyyH2FyutKF7_-stdl05Ux6SO5SjVWonzAimWihgoaoV85WhCzNJ6mY_CtjUL93ir6RE='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOptVWoaz_2VlHc7_PbzgGy8kndJ4MF80wjFjKNY_Dd9M2JxPqUzwb0B5O50KcbV446m1oNKccuaFR1dQiLCSp-a8R9_Pn3GszfZS3gkYkgdS66eGmlgTKoKpYwP_blPiU3eEX2QR-aHEN1ye2V2E9nRRW1LbWh6cCTXrOXkzop8vEgf-oVP6ZutcDY8q8vw2a5xg='},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiLxtIpm2qJtmMnhqBJ9YcYcyvGKORaBIWOQK6IXnqWEKdgA52dmNWwhUVpThpIlQXga0CTXTP1XYVKF68bJ6x2vatxYXH3GTX476iG53wE-7gdiDZlz3i67mFHCjYzWFdZUJIqtlXaKA3nwxZpQPxduvnYnFSvC7fyL4tWp3ijvBhs_0Zy-aTfCRv4xZBrJUf_n622c0gTnw='},\n",
       "  {'label': 'researchgate',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-_J3R15x3KGAql8zP1nVfG9Rp2PHpaHmco9hTIwNw2xMQw5SRVQp28UmEQEy9Z6lOQI4vwoVYhXwtdUaPu6LTZ8K3-x2VaMuQY84AbUebxkkPkPi9-taJmq0EVxyuVouAS0qbA_I6iGhvFtV_H6Yy31kb1Gs9fz0E_rQg4_EiTV3SWTqxxCNrAccQgTu5ENEU-GZc0tNCEcWD2R-fZbGsCvz4v8XooiFVLgRwPA5fjRuna-FEE8UFyfA_mrnD49vQncg7DMdK0Dx8uVVBJaHpSCZ6IGk_SklnNQU2pDn7WoCkq8TjifsRELgvshktv06ndvXlWHmoVUSE'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWTYiUV5_oFRjEBz7VwucSCug9C0Kxqrt1k5uRw3g00zlmKvsZKu213MVh5Jp5Cs-LxJWeHMPUMUMOMfywmmH541TW6QL5QHf_LZgXY85gaZhHCU2xiPlrHrfMs58o1AtaZWenjiFZnqQ1IZU='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWTYiUV5_oFRjEBz7VwucSCug9C0Kxqrt1k5uRw3g00zlmKvsZKu213MVh5Jp5Cs-LxJWeHMPUMUMOMfywmmH541TW6QL5QHf_LZgXY85gaZhHCU2xiPlrHrfMs58o1AtaZWenjiFZnqQ1IZU='},\n",
       "  {'label': 'researchgate',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-_J3R15x3KGAql8zP1nVfG9Rp2PHpaHmco9hTIwNw2xMQw5SRVQp28UmEQEy9Z6lOQI4vwoVYhXwtdUaPu6LTZ8K3-x2VaMuQY84AbUebxkkPkPi9-taJmq0EVxyuVouAS0qbA_I6iGhvFtV_H6Yy31kb1Gs9fz0E_rQg4_EiTV3SWTqxxCNrAccQgTu5ENEU-GZc0tNCEcWD2R-fZbGsCvz4v8XooiFVLgRwPA5fjRuna-FEE8UFyfA_mrnD49vQncg7DMdK0Dx8uVVBJaHpSCZ6IGk_SklnNQU2pDn7WoCkq8TjifsRELgvshktv06ndvXlWHmoVUSE'},\n",
       "  {'label': 'researchgate',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-_J3R15x3KGAql8zP1nVfG9Rp2PHpaHmco9hTIwNw2xMQw5SRVQp28UmEQEy9Z6lOQI4vwoVYhXwtdUaPu6LTZ8K3-x2VaMuQY84AbUebxkkPkPi9-taJmq0EVxyuVouAS0qbA_I6iGhvFtV_H6Yy31kb1Gs9fz0E_rQg4_EiTV3SWTqxxCNrAccQgTu5ENEU-GZc0tNCEcWD2R-fZbGsCvz4v8XooiFVLgRwPA5fjRuna-FEE8UFyfA_mrnD49vQncg7DMdK0Dx8uVVBJaHpSCZ6IGk_SklnNQU2pDn7WoCkq8TjifsRELgvshktv06ndvXlWHmoVUSE'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWTYiUV5_oFRjEBz7VwucSCug9C0Kxqrt1k5uRw3g00zlmKvsZKu213MVh5Jp5Cs-LxJWeHMPUMUMOMfywmmH541TW6QL5QHf_LZgXY85gaZhHCU2xiPlrHrfMs58o1AtaZWenjiFZnqQ1IZU='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkB6yDTxC4HTfXXoN-HhsNDICXKGHYL4ddE4Rs2qjPfrtO3oPSJP9diyQqX9TjtGddkKATmoD7Ei1jv-tM2da4qhvT-HYjxc1pXZlMl2YhX260JUJSU0fZ93WnDenSafEtc54='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWTYiUV5_oFRjEBz7VwucSCug9C0Kxqrt1k5uRw3g00zlmKvsZKu213MVh5Jp5Cs-LxJWeHMPUMUMOMfywmmH541TW6QL5QHf_LZgXY85gaZhHCU2xiPlrHrfMs58o1AtaZWenjiFZnqQ1IZU='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkB6yDTxC4HTfXXoN-HhsNDICXKGHYL4ddE4Rs2qjPfrtO3oPSJP9diyQqX9TjtGddkKATmoD7Ei1jv-tM2da4qhvT-HYjxc1pXZlMl2YhX260JUJSU0fZ93WnDenSafEtc54='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWTYiUV5_oFRjEBz7VwucSCug9C0Kxqrt1k5uRw3g00zlmKvsZKu213MVh5Jp5Cs-LxJWeHMPUMUMOMfywmmH541TW6QL5QHf_LZgXY85gaZhHCU2xiPlrHrfMs58o1AtaZWenjiFZnqQ1IZU='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkB6yDTxC4HTfXXoN-HhsNDICXKGHYL4ddE4Rs2qjPfrtO3oPSJP9diyQqX9TjtGddkKATmoD7Ei1jv-tM2da4qhvT-HYjxc1pXZlMl2YhX260JUJSU0fZ93WnDenSafEtc54='},\n",
       "  {'label': 'researchgate',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-_J3R15x3KGAql8zP1nVfG9Rp2PHpaHmco9hTIwNw2xMQw5SRVQp28UmEQEy9Z6lOQI4vwoVYhXwtdUaPu6LTZ8K3-x2VaMuQY84AbUebxkkPkPi9-taJmq0EVxyuVouAS0qbA_I6iGhvFtV_H6Yy31kb1Gs9fz0E_rQg4_EiTV3SWTqxxCNrAccQgTu5ENEU-GZc0tNCEcWD2R-fZbGsCvz4v8XooiFVLgRwPA5fjRuna-FEE8UFyfA_mrnD49vQncg7DMdK0Dx8uVVBJaHpSCZ6IGk_SklnNQU2pDn7WoCkq8TjifsRELgvshktv06ndvXlWHmoVUSE'},\n",
       "  {'label': 'researchgate',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-_J3R15x3KGAql8zP1nVfG9Rp2PHpaHmco9hTIwNw2xMQw5SRVQp28UmEQEy9Z6lOQI4vwoVYhXwtdUaPu6LTZ8K3-x2VaMuQY84AbUebxkkPkPi9-taJmq0EVxyuVouAS0qbA_I6iGhvFtV_H6Yy31kb1Gs9fz0E_rQg4_EiTV3SWTqxxCNrAccQgTu5ENEU-GZc0tNCEcWD2R-fZbGsCvz4v8XooiFVLgRwPA5fjRuna-FEE8UFyfA_mrnD49vQncg7DMdK0Dx8uVVBJaHpSCZ6IGk_SklnNQU2pDn7WoCkq8TjifsRELgvshktv06ndvXlWHmoVUSE'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkB6yDTxC4HTfXXoN-HhsNDICXKGHYL4ddE4Rs2qjPfrtO3oPSJP9diyQqX9TjtGddkKATmoD7Ei1jv-tM2da4qhvT-HYjxc1pXZlMl2YhX260JUJSU0fZ93WnDenSafEtc54='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ZvomTCYYiw9eF6J5Kd6bpG4WDBiDBnhogWgGFEVw1an0Hmf9xZSKkF3_P6BfeGIGqph_kV2HTx1PNrGp20y-TK0rYb3tSymn6EbDPvyMmL4qHhOTSpav6Qd99opPuoAhliVdf29QTVuuLus='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPQS-7z8lisFQWsMtVGyi4lYAhRwcUq8fCbuf8CP_yjCjfHLZ0f0ATVL7Ca2wITi2UTnn9jizz1B6Z_Uv6RBXS-KWkJSscf8tLchjrJlLrOM0ik63hCDaMVlTES9f3GP6YtnpUyg3_id_eJnFfDo3h4XSvR4rTaFQ0mlZTpSXBEvtrsuJM6H0B0wP0cU1d7N6A8YpMcYs='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUIsPmI7ngyIpXSy8Hff7CmWOo8hmoq9VraVXGAwvM4suneM5sYzd-CouxBmhPhOt6OL42EUhJSIyNYbiKgWtAqr-B-GuTWP3jHRzcilEDbI_8Qs6RMVrPWR7Sff6PDx_3PQ=='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUIsPmI7ngyIpXSy8Hff7CmWOo8hmoq9VraVXGAwvM4suneM5sYzd-CouxBmhPhOt6OL42EUhJSIyNYbiKgWtAqr-B-GuTWP3jHRzcilEDbI_8Qs6RMVrPWR7Sff6PDx_3PQ=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEVII3OhdqvxnMTyaOSf4nS8puR3IE7ddZkv0g4GFcgiF8O_ZlSthJqlQzBAz5_PB4WNf7zGuNc805rhBgeDBVBKIDRIUkDRPw0LjzJySoOYT7Sx5pGOCIAzoUnvhUCxtVIiyPuspw8FAaQiFBIOwtaPNUAjCYzu9x8lxlN8y9WEhKf5mlRgP7m5TljXXBSbXcsYNgGRIpauS5u4tkN45x3lR_RdUIwwl8='},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQaUX6WYmdzR0cGboIm4gnfjP77982ONoOoVD_BnWYd0TKSKctlxlK2p18qccJP3BdHLqWWgkTaOrtMJsltXu-z0qUWDiUB4SDKbI5TweUObn87_GpUacGnkbZJ2n_GH8gXjhjLWZp9_q6ItRUZHTC3wPAY6zyvQGL0WVU_DRDzqdHJ9PMSSoymLYE_eQupw=='},\n",
       "  {'label': 'iwmf',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSbMeLEeiE_YlJkBkmo9Ju6Qq-FuIZEuIMpGxt46YX9t1c4Z3_UlfhwobCOCATbGHdKRtXrQ-4LXzKBpBdrcjEs919l4N-5SsudPL3dIcJqVSTJhdf45jdfdK269Bwg4LjenyPaPEaQ3sS853t-R0UIUMjGagsKxgY_BpfZ_hvJszTqm2GzGBTeDSminUPAaKgnclk3LhX37XIsb6qySpheiwhJ7phBgkoqngV89gyhPLDETvwZAuqQVmM81IH_TwR4bUZ3rUE7bEhS94GvIziDk-oqAz_0Nb9_DE='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ZvomTCYYiw9eF6J5Kd6bpG4WDBiDBnhogWgGFEVw1an0Hmf9xZSKkF3_P6BfeGIGqph_kV2HTx1PNrGp20y-TK0rYb3tSymn6EbDPvyMmL4qHhOTSpav6Qd99opPuoAhliVdf29QTVuuLus='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8xHWl_PnGql7MUZI3EuXZ4FLxQwjgKYT6TzbRBpSI5mMtztMP-nLOHh8YtdJtdntFX_w3xFMTxtY2uaAxqi5bxRqfI55EsYMa5bb3_s1WsgV7MkxQSY9qsnLZ5bdG7s1eDCyhf_0QH7E0NXpsvltiNMkeZmf2HVDXzms3pojkI20xfhxxMarKdri6dqEodhYSDA=='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ZvomTCYYiw9eF6J5Kd6bpG4WDBiDBnhogWgGFEVw1an0Hmf9xZSKkF3_P6BfeGIGqph_kV2HTx1PNrGp20y-TK0rYb3tSymn6EbDPvyMmL4qHhOTSpav6Qd99opPuoAhliVdf29QTVuuLus='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-21',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHPj8l0s1DQl7KFt4TYejbBB9pLcqZ0NAbsx3QQZ1S_gKfaiMhafDrjBPtG7LM-HEVGX3lCxXmbLSbB9h8avWUM6uJWxFF9Ka49xHQyJWBuD-2qAJUaOdRPJzfD-SYLqOlmAjg='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ZvomTCYYiw9eF6J5Kd6bpG4WDBiDBnhogWgGFEVw1an0Hmf9xZSKkF3_P6BfeGIGqph_kV2HTx1PNrGp20y-TK0rYb3tSymn6EbDPvyMmL4qHhOTSpav6Qd99opPuoAhliVdf29QTVuuLus='},\n",
       "  {'label': 'cancernetwork',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-22',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6eFW9rbMttpPwYRzz9Ldi0F65UKUrs-7P1BAozPBjHRn7o1_7BPA01AXOccptY2tBV3mejnux3C3pC30ARJjb6pJkGLa__kPEQ_bIdD002rI48MuiZGbhgmAWcweUHuya9wDzRSEeJ9tfxSytB6MLysqnMyqzA-toFOo6dNv8uYLhru2Fp6bLD6o_xDPTwDXIuhIu0d5grNCf8CtE_AM2VKR0jlVZYEo='},\n",
       "  {'label': 'lymphoma',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E='},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ=='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMVUS8lGgTxBgiqGz0YuVZDW51UIjKC3sUJP2qptikwwQ5YJ3-7lT_qSJJv1RCH1qwbysN1xeIoOpMKOC69rsBnHhXuxagEBB59veyAlrZhWI9VKBLLjUfo2ePTy8vokAdqVuStrBi4qZwtg42z5L96JENJvwGDww='},\n",
       "  {'label': 'cllsociety',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg=='},\n",
       "  {'label': 'nurixtx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-JgsLVY6qxEpKoizDonaGVNgbnxNkBmWCY0tCwDksYpf9LOWh9wDeiRzHW3IwFOMRLnaWZML8pAnnF0SPllvM1mh8epO19PmQ14ng0UwTs-oT-RsXR7koSJqvcBYYbptmUUarE5Nq6YyZGSDG5t7Uq_kwEOaA9y4g8V072fkd4fPdusFAikHeNjHxu-XJTX1sJuqijMoeUCMBY3220ehVm2ohOTT3UXlGDw=='},\n",
       "  {'label': 'ascopubs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1iFL5oo39UiFgsaSNBtPdJApLTVrb4Q2kOB6POyY5VeAhX0Rbh92Tswf3yjVLjDt7ahyJPT65vVV7ml1fTsAt2qL8yTbasOj_NVa56fPRK23KjXucwLoaEXgmVQltc17caiLb30nWJvFGsRBjqU1ls0dcvVMAozmsebHfof55sviqmw2JDCrWh0s7CXcANZAp4p3PtkRSI0Iu3KHB-EXhMbZoo6r5k8UgOARk7akGAQ=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOaWY1mtM3ecBCUSnypB05vs3dJ8zBbepgvL_cI7wxSydlKw0ICG1QmzWhrm7dXCUBb0NtQhhT1EZLE_ZpbHQmYTjZicEYa551y-iQI0Y4sHVWQQN8_MNwfcaxXdhDWf9dZo5yHw=='},\n",
       "  {'label': 'mdpi',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWFaKT_dXLe_ku-nu2OwFKkht3MJ4DW9u0JQEK9SwUT2hT03959Mrya76hkd5sFE8akKGtj8gQNtdqzAvpP7CcLDj1-kc_K_qkbfoE45xtXuNSKpSRV99XYdknW6CjwMV5'},\n",
       "  {'label': 'ajmc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOFkLkSvvn7iN6oLkkJmO73AF3fIdB5ypBGSMAzyojkSOdN-ZJdZADQZSgtQmpq3L9bj5efL1XvjkI4_aEnTxfag7Hvo-nedOBQJGbpbecImybmKSflOlDy6xvMqhpHFFdb1-O7fAVT2rPF75JVJFwzz-U3WcocL14xwdu8krZGWoZMbd6uWVzlJGYoL4WH5r1YO85WAFfNP3V4QU0mOSVDHY='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw=='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg=='},\n",
       "  {'label': 'targetedonc',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw='},\n",
       "  {'label': 'oncologynewscentral',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW'},\n",
       "  {'label': 'cancer',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk='},\n",
       "  {'label': 'lls',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk='},\n",
       "  {'label': 'ashpublications',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc='},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ='},\n",
       "  {'label': 'healthtree',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g'},\n",
       "  {'label': 'nih',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g='},\n",
       "  {'label': 'bloodcancerstoday',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ=='}],\n",
       " 'initial_search_query_count': 3,\n",
       " 'max_research_loops': 3,\n",
       " 'research_loop_count': 2}"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "As of July 2025, the treatment landscape for Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) and Small Lymphocytic Lymphoma (SLL) is characterized by a growing number of targeted therapies and innovative approaches designed to improve outcomes, especially for patients who have progressed on previous treatments [ajmc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI=). Treatment decisions are increasingly personalized, taking into account prior therapies, disease characteristics, and the patient's overall health [lymphoma](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E=) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==4).\n",
       "\n",
       "### **FDA-Approved Therapies for R/R CLL/SLL**\n",
       "\n",
       "Several targeted agents have received FDA approval for treating R/R CLL/SLL, offering significant advancements over traditional chemotherapy.\n",
       "\n",
       "*   **CAR T-Cell Therapy**: Lisocabtagene maraleucel (liso-cel; Breyanzi) is the first CAR T-cell therapy approved for adults with R/R CLL/SLL. It is indicated for patients who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG39a6UkdgWLbRPIwaTE6oqq7VqXGtiD88BT5OFvrKS2iei21fRAQ-N2UsC9LJBITb7G3_-ITZDkc6LQ7ogSWhzCwwveHvD3u99CDkfKvHSQ90Ncj-yRwAqQa6-w0UoaP9pBa6KuKStCJRCyJtj7ThNO7I0GO8-H9z4XQGilxGPPTAdzqs22qeSwD-uYkCPR4payPw=) [oncologynewscentral](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpF4qaBc8NstZB4ABNj6MHchLsKstq2kMWMyMUslbCGMVNW0_v4e3rgfMhQNuZMmaKbARumN8OYfP9N0q_ZEgOZNGAgyctENkY3i12PQizQ6V9otFJyp6hXxOJY1sMcp6tw4q7E7nrUAm_0LERlWzL4-N4oFWDvZgj2pD44bb6tVY_2vrmlbkHW9zxQuqLAkoBMACu1CaW). This approval was based on the TRANSCEND CLL 004 trial, which demonstrated significant improvements in response rates and survival [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==0) [ajmc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOFkLkSvvn7iN6oLkkJmO73AF3fIdB5ypBGSMAzyojkSOdN-ZJdZADQZSgtQmpq3L9bj5efL1XvjkI4_aEnTxfag7Hvo-nedOBQJGbpbecImybmKSflOlDy6xvMqhpHFFdb1-O7fAVT2rPF75JVJFwzz-U3WcocL14xwdu8krZGWoZMbd6uWVzlJGYoL4WH5r1YO85WAFfNP3V4QU0mOSVDHY=).\n",
       "*   **Non-Covalent BTK Inhibitors**: Pirtobrutinib (Jaypirca) is a non-covalent (reversible) BTK inhibitor that has received regulatory approval. It is effective in heavily pretreated patients, including those whose disease has progressed on covalent BTK inhibitors (like ibrutinib, acalabrutinib, or zanubrutinib) and BCL-2 inhibitors [bloodcancerstoday](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ8EaN1dJc2wETeC5bWkSBegFCGxbiOOdHWYnGbzaPVHGeHGU6TqO4G3c4BONm-0GinlbwSErrN4WjXbiEyl8q1JE2_7F8zIKAkFzBZEA8SoIST0L1O1ENJTABnDjavlrL17C6AvW0cyjd7YJL7BuExhX9z7XMbvEz-PQ1m4DQf88FhAZdJJXHcGVtAjJj2xRoWg==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw==0). The phase 3 BRUIN CLL-321 trial showed that pirtobrutinib improved progression-free survival compared to standard chemoimmunotherapy or idelalisib-based regimens [ascopubs](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1iFL5oo39UiFgsaSNBtPdJApLTVrb4Q2kOB6POyY5VeAhX0Rbh92Tswf3yjVLjDt7ahyJPT65vVV7ml1fTsAt2qL8yTbasOj_NVa56fPRK23KjXucwLoaEXgmVQltc17caiLb30nWJvFGsRBjqU1ls0dcvVMAozmsebHfof55sviqmw2JDCrWh0s7CXcANZAp4p3PtkRSI0Iu3KHB-EXhMbZoo6r5k8UgOARk7akGAQ==).\n",
       "*   **Next-Generation Covalent BTK Inhibitors**: Zanubrutinib (Brukinsa) is approved for both newly diagnosed and R/R CLL/SLL [lls](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk=). It has shown a better response rate and improved tolerability compared to the first-generation BTK inhibitor, ibrutinib [cancer](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk=) [lls](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMyoGvNssTGjnJXQre_wwu5YF3KMusUBX3qtlKLlT1wQX0kLXQ4RGKcpKXtBO2J2q1vlPL4s0e12fv9ey7fWyGHisKlX8MFhZz0cf2_KLozNJh0ExNmwTRhumfoRvmYvldoKdRPIJMOZD8NjHKCGu-l5TXkCIKfJh4JarnrOk=). Other approved covalent BTK inhibitors include acalabrutinib and ibrutinib [cancer](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQDrR5l4aLV5vRj6qcZ3RGe9r8lH7hOhexKyjmwMKJIduC-YXlQmvY9b2LlSPY6br728YPG-vjmCPUfBXjDANDQ4BnDSnv5nsALw_pgB7PR1Z_wfytueCay-9ihkZc2gYSyRuZmQNrYPO-oDW0rnM2YuT0yTDMLbaQxv8dUm3i1l2zImLodtb2iNrLTlJ6jwk=).\n",
       "*   **BCL-2 Inhibitors**: Venetoclax is a key BCL-2 inhibitor used in treating R/R CLL/SLL, often in combination with a CD20 monoclonal antibody [mdpi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWFaKT_dXLe_ku-nu2OwFKkht3MJ4DW9u0JQEK9SwUT2hT03959Mrya76hkd5sFE8akKGtj8gQNtdqzAvpP7CcLDj1-kc_K_qkbfoE45xtXuNSKpSRV99XYdknW6CjwMV5) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqow7vEjL_6lP6rU-j7ZWNktnx5mLNsxaEaAFQnikP9TQg_TG8oTz3fDMxXJ3U3RjP8QuB9IbwTSw5QhG7PUYuzyk9T4BNfRs__NGN0HzS55LGmeM1M5MrDlrSoJP8KTn52Q9g8ydMEfWqhpI=).\n",
       "\n",
       "### **Ongoing Research and Clinical Trials**\n",
       "\n",
       "Active clinical trials are exploring the next wave of therapies aimed at overcoming resistance and further improving patient outcomes.\n",
       "\n",
       "*   **BTK Degraders**: This new class of drugs aims to completely eliminate the BTK protein, offering a potential solution for resistance to BTK inhibitors [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g). NX-5948 is a promising BTK degrader that has received FDA Fast Track designation for heavily pretreated R/R CLL/SLL patients, with pivotal studies planned for 2025 [nurixtx](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-JgsLVY6qxEpKoizDonaGVNgbnxNkBmWCY0tCwDksYpf9LOWh9wDeiRzHW3IwFOMRLnaWZML8pAnnF0SPllvM1mh8epO19PmQ14ng0UwTs-oT-RsXR7koSJqvcBYYbptmUUarE5Nq6YyZGSDG5t7Uq_kwEOaA9y4g8V072fkd4fPdusFAikHeNjHxu-XJTX1sJuqijMoeUCMBY3220ehVm2ohOTT3UXlGDw==). Other degraders in trials include NX-2127 and BGB-16673 [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g).\n",
       "*   **Novel BCL-2 Inhibitors**: Sonrotoclax is a next-generation BCL-2 inhibitor showing high efficacy. In combination with zanubrutinib, it has demonstrated a 97% overall response rate in R/R CLL/SLL [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm_0d4GzFRSy2wH6K2ioQxmAEze5ZELTW7v6sxB5Yht4HZMpM_SSb08Tc0ySvW88Z9p2aZXnBPwNYw8-3z-IksaLrS6tdTRBN78YJzFat_Gx7T2831tshKgxr46OdxaMW8KamqhKO3MLh9F5FvaGpIU8QO5DsUFgD_NnXhtL4F8XyxVeTXFg==). Updated data shows a 30-month progression-free survival rate of 94.7% in a high-risk patient group, with encouraging safety [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOaWY1mtM3ecBCUSnypB05vs3dJ8zBbepgvL_cI7wxSydlKw0ICG1QmzWhrm7dXCUBb0NtQhhT1EZLE_ZpbHQmYTjZicEYa551y-iQI0Y4sHVWQQN8_MNwfcaxXdhDWf9dZo5yHw==).\n",
       "*   **Advanced CAR T-Cell Therapies**: Research continues to refine CAR T-cell therapy. A phase 1b trial is evaluating an allogeneic (\"off-the-shelf\") CAR T-cell therapy, azercabtagene zapreleucel (azer-cel), in CLL/SLL patients [targetedonc](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==1).\n",
       "*   **Combination Therapies**: Numerous trials are testing novel combinations. One trial is assessing the safety of RP-3500 plus olaparib in R/R CLL patients with high-risk genetic mutations [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==2). Another study found that combining the bispecific antibody epcoritamab with venetoclax resulted in superior killing of CLL cells compared to either drug alone [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8sYet2-tvU5d5el-4LElIUJy0CLbTsmUz5SO9HhubRQr7K5PLImcEYHVkN22xCOnNIZaXPBIkDRt-6BKuNMmjOppcTcDIBpvQqc152mrRw54SpuY4FKNWX3BBM7I-8PhIetbBS59i3GOe0e5yNI3ZuH9QXKygOy1sXfZveQ==3).\n",
       "\n",
       "### **Strategies to Overcome Treatment Resistance**\n",
       "\n",
       "As targeted therapies become standard, understanding and overcoming resistance is a major focus of research.\n",
       "\n",
       "*   **Resistance to BTK Inhibitors**: Covalent BTK inhibitors like ibrutinib and zanubrutinib can be rendered ineffective by a C481S mutation in the BTK protein [ashpublications](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIBbYFmVt-4gsI3m5RlrnyUiaORkU8279NAmlWdGdeJDNhB9ODJWetAG5qZyVDG07uv4uRVM4eC2-LMQ4A3h2Qvs2O6covQ3PJZAi5D7qQr1hO02qKiIdZfezLS5gkI3LEEhpI4q744723MHYRwe6FgEMiM_024iKLWGbbl58G4T0b2JJXtz0zMhFFVT_DFvA15P_sl2QIREJsX9ZzVPK4E_LfWYvHnwc=). Non-covalent inhibitors like pirtobrutinib can overcome this specific mutation but may be susceptible to other, less common BTK mutations [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=). BTK degraders are being developed to destroy the BTK protein entirely, bypassing these mutation-based resistance mechanisms [healthtree](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9O6VJ7k1FIrHZRDQFJdaLvMyotUNQXNzyvcXAK9KmwlRBdpVrZss0QZEFfksdhiIlocdlPRe-ZEudTiCQAop6sxZgadgPPb0Nc6Dy1JT14GSYLyBdCyyLSyNLI-Usbm3kwtOOBirxvMWOy5Vxu3D2yIBoLFC11DoJ-8MofDrvzff2kU7LzgmoaM8g).\n",
       "*   **Resistance to BCL-2 Inhibitors**: Resistance to venetoclax is often driven by a G101V mutation in the BCL2 protein [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g=). Novel BCL-2 inhibitors like sonrotoclax are designed with a different binding mechanism that maintains potency against this mutation [bloodcancerstoday](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHshuHEYhzEq_N3EoTm9EwvDftic9twx2spjEqq5BfPkRNBE5my5gS8WLmEa1vh5SU6KSlLkKO4xBfUSWElzzhT5Ty_C2TE7qluZ3trSFeICHRo9BTyCOvoK1LXgTtbMUlguZQh6HOOweAtNkC-iXziRYs0CRAf-BFTULJSUj5gM9S5J9MqDdeFVBbsIR4IezGp9eIRfz-aXjCtLF6Y3U_2D8nOHLGfbTo-fHq5AMoiGdbKPak3CyeyiQ==) [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1MM-ZCzSozyq4Axk5bdHTbA7XLQbONR5_n142zyp-2uY3o7fYVTTN6KeFQyglqHd-WfRjctdUVlWHREphY6FuPYf6JkM9B0GRnoZd2Pim_8VVymzTuTVUgtrshkd88PnpC4g=).\n",
       "*   **Resistance to CAR T-Cell Therapy**: Resistance to CAR T-cells can occur through several mechanisms, including the cancer cells losing the target antigen (antigen escape), CAR T-cell exhaustion, or suppression by the tumor microenvironment [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=3) [researchgate](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=2). Strategies to combat this include developing \"armored\" CAR T-cells that are more resilient, creating CAR T-cells that target multiple antigens, and combining CAR T-cell therapy with other drugs to boost their function and persistence [nih](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=4) [mdpi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfVtQ6Q3WHwZSZOE4waNd0b6_V7J5G5dfy-Ch_7gXRX6mrMLskxp5ezVbzE1OBtBtXW-pMHvGRv6EgYR_IHN9J3YmPvmiwD2drqekwyMMkNOqsVv91tV2Rwh-_2pCM1dnMpQ=6).\n",
       "\n",
       "Given the rapid pace of development, participation in clinical trials remains a crucial option for patients with R/R CLL/SLL, offering access to the next generation of therapies [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEs1hLFNfRaGl-RY5TI5Fjuhj_u5TBoVRSl5uFYw_syMH6IFukYdrdHAdpNQwlK_hpHv7Pbnp05njh0k_jB62mHbFS_sYTTcN2v96hNjK3zjONUHXM0GzKFEE_Fsrcze2-fm2WFs7rqE0_zFFMGjw0WePeMShhTPPVnglyH5wSLEKchb79i7w9pYKQxt9e6TxcTFCegmYe2R8FzmHrOMcpmBw==1). Patients are encouraged to discuss these ongoing treatment options and clinical trials with a CLL specialist [cllsociety](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMVUS8lGgTxBgiqGz0YuVZDW51UIjKC3sUJP2qptikwwQ5YJ3-7lT_qSJJv1RCH1qwbysN1xeIoOpMKOC69rsBnHhXuxagEBB59veyAlrZhWI9VKBLLjUfo2ePTy8vokAdqVuStrBi4qZwtg42z5L96JENJvwGDww=) [lymphoma](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZD_KVGCzxBoBL3rGNBKjjay96p1G3v_csT3s67L2tWBw8qAyRdZuG-ZUc-3PqvAjcV2IityEBrl3uAlLzVsg0zpZTR5ENZ4vmgqaH_ZOK7i8i2-qLIACiPV4KthZD8IhGJuEED7t57nZEv_M0ZbejRYlMxiPANieE2f860il-nW0UUUp0cte89LvD_t5cNff-NLJQmMTt88E=)."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from IPython.display import Markdown\n",
    "\n",
    "Markdown(state[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "state = graph.invoke({\"messages\": state[\"messages\"] + [{\"role\": \"user\", \"content\": \"How has the most titles? List the top 5\"}]})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "As of July 10, 2025, Spain holds the record for the most UEFA European Championship titles with four victories [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAqgnv65rL4mmdye2Fq3pM4I2FhI2IzAKP-bDb5dWqBRbcjYSulFbL9eqjQeVV_V9ZoatvfQCf4Eo0CAC2w8_iR1-D0KW8kQej8GFvyYPXO5M366SlESxdySH3MJp8GpplTmgJrX0Q0sfhLGztY4ciMTKo) [givemesport](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoyXT0BqqBhWPa9l4qbEHrFA1XZyL8hekYvbsDFA8wZZDTKpai1acGpFN80r_4aJHovptSMNPFtGU98zTbwZn7Hv6c7K8QUy-6TIslw1ZD1EyYUi2EEKzPslk6-2WtyBbbo4ktCizj-UHLHeHgUtk-Suc5axnbcJWcl1Q4bVQ=) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwhGF8iY-pLWNAf1z-KYfkIqAokqJ_cUyLEWpoIzcbIzj8W0jomYOvHMAOx9tBE_2JDpcMZ-5l5SroKpzo7e6EYzarsnYDqZ_ZZoQNDNigLozGcCchxOcfhf419P7ShEgbn86qbGKhpih2bEpkn4HUtPOTwSKEaAkdDv9vikMFIi1R6MnROTlWugstmHPbP_2xmiE=). Their most recent win was in the 2024 tournament, where they defeated England in the final [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwhGF8iY-pLWNAf1z-KYfkIqAokqJ_cUyLEWpoIzcbIzj8W0jomYOvHMAOx9tBE_2JDpcMZ-5l5SroKpzo7e6EYzarsnYDqZ_ZZoQNDNigLozGcCchxOcfhf419P7ShEgbn86qbGKhpih2bEpkn4HUtPOTwSKEaAkdDv9vikMFIi1R6MnROTlWugstmHPbP_2xmiE=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAqgnv65rL4mmdye2Fq3pM4I2FhI2IzAKP-bDb5dWqBRbcjYSulFbL9eqjQeVV_V9ZoatvfQCf4Eo0CAC2w8_iR1-D0KW8kQej8GFvyYPXO5M366SlESxdySH3MJp8GpplTmgJrX0Q0sfhLGztY4ciMTKo).\n",
       "\n",
       "Here are the top five nations ranked by the number of Euro titles won:\n",
       "\n",
       "1.  **Spain** - 4 titles (1964, 2008, 2012, 2024) [givemesport](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoyXT0BqqBhWPa9l4qbEHrFA1XZyL8hekYvbsDFA8wZZDTKpai1acGpFN80r_4aJHovptSMNPFtGU98zTbwZn7Hv6c7K8QUy-6TIslw1ZD1EyYUi2EEKzPslk6-2WtyBbbo4ktCizj-UHLHeHgUtk-Suc5axnbcJWcl1Q4bVQ=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE99WZ9N426TCMk1_qrscYxw-qcNw7MYZ5ly2iWScDCP7UJRgVSFyVTfwdgOPViQ2gszgsAb883bqPfzz6lDjXaopUloFndpCqKzduwR_kApywUkvwDNkZVIN4w-AEihwbCOK6H366dw1aITYPCwJlxb3toy6tEFxjL-8Wq1ajQ-3ua)\n",
       "2.  **Germany** - 3 titles (1972, 1980, 1996) [givemesport](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoyXT0BqqBhWPa9l4qbEHrFA1XZyL8hekYvbsDFA8wZZDTKpai1acGpFN80r_4aJHovptSMNPFtGU98zTbwZn7Hv6c7K8QUy-6TIslw1ZD1EyYUi2EEKzPslk6-2WtyBbbo4ktCizj-UHLHeHgUtk-Suc5axnbcJWcl1Q4bVQ=) [byfarthegreatestteam](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8v_dJIwJbUcW6DWt_9fpPbXVd3EFM_2gfunqsx9V0Ql0zZnPsP9wt7k7MJyBU4eZtAQCH7E2HlQuar_8-XCgkB3NqRurg82VdFIUNaPaZFyRUn-7v6AQ4lG8Y8nsYqR23UqQY_0KySTkzSMEcBowgwcF3FVths6ih1NTLiZni1sMCat11b9Mn16d06Pz07oSYy6kNVYe20bGIsD7bEBMxc0FDoLR3hsu5i_qJN0moo4_1notZ)\n",
       "3.  **France** - 2 titles (1984, 2000) [byfarthegreatestteam](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8v_dJIwJbUcW6DWt_9fpPbXVd3EFM_2gfunqsx9V0Ql0zZnPsP9wt7k7MJyBU4eZtAQCH7E2HlQuar_8-XCgkB3NqRurg82VdFIUNaPaZFyRUn-7v6AQ4lG8Y8nsYqR23UqQY_0KySTkzSMEcBowgwcF3FVths6ih1NTLiZni1sMCat11b9Mn16d06Pz07oSYy6kNVYe20bGIsD7bEBMxc0FDoLR3hsu5i_qJN0moo4_1notZ) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE99WZ9N426TCMk1_qrscYxw-qcNw7MYZ5ly2iWScDCP7UJRgVSFyVTfwdgOPViQ2gszgsAb883bqPfzz6lDjXaopUloFndpCqKzduwR_kApywUkvwDNkZVIN4w-AEihwbCOK6H366dw1aITYPCwJlxb3toy6tEFxjL-8Wq1ajQ-3ua)\n",
       "4.  **Italy** - 2 titles (1968, 2020) [givemesport](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoyXT0BqqBhWPa9l4qbEHrFA1XZyL8hekYvbsDFA8wZZDTKpai1acGpFN80r_4aJHovptSMNPFtGU98zTbwZn7Hv6c7K8QUy-6TIslw1ZD1EyYUi2EEKzPslk6-2WtyBbbo4ktCizj-UHLHeHgUtk-Suc5axnbcJWcl1Q4bVQ=) [byfarthegreatestteam](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8v_dJIwJbUcW6DWt_9fpPbXVd3EFM_2gfunqsx9V0Ql0zZnPsP9wt7k7MJyBU4eZtAQCH7E2HlQuar_8-XCgkB3NqRurg82VdFIUNaPaZFyRUn-7v6AQ4lG8Y8nsYqR23UqQY_0KySTkzSMEcBowgwcF3FVths6ih1NTLiZni1sMCat11b9Mn16d06Pz07oSYy6kNVYe20bGIsD7bEBMxc0FDoLR3hsu5i_qJN0moo4_1notZ)\n",
       "5.  **Six countries** are tied for fifth place with one title each [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAqgnv65rL4mmdye2Fq3pM4I2FhI2IzAKP-bDb5dWqBRbcjYSulFbL9eqjQeVV_V9ZoatvfQCf4Eo0CAC2w8_iR1-D0KW8kQej8GFvyYPXO5M366SlESxdySH3MJp8GpplTmgJrX0Q0sfhLGztY4ciMTKo) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFU8X0WzzfcvPYk6rFcuM50hKEKdIk6fsuBys9f2gJrm9WIBZPicOIfZXwjReQOVAb2o6_2wLgjglF7Wc-2p3_pVFI7VTfqY1Ooga31CvaJmZcI9eNNyA3vcDmBS7dGbVxR37NJ1tpEyirWLLT43N2PHndobMC3ZPq5Z5oh3nINh_BRg5PpJ60FDWd5TBgk6VvEe8sIv51Us5Yg-Y9VTXiis75H9kpbvPrapgzWq_KvK8eJ9aXjQrDot9c7dsjBGqnMWD0=) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwhGF8iY-pLWNAf1z-KYfkIqAokqJ_cUyLEWpoIzcbIzj8W0jomYOvHMAOx9tBE_2JDpcMZ-5l5SroKpzo7e6EYzarsnYDqZ_ZZoQNDNigLozGcCchxOcfhf419P7ShEgbn86qbGKhpih2bEpkn4HUtPOTwSKEaAkdDv9vikMFIi1R6MnROTlWugstmHPbP_2xmiE=):\n",
       "    *   Portugal (2016)\n",
       "    *   Greece (2004)\n",
       "    *   Denmark (1992)\n",
       "    *   Netherlands (1988)\n",
       "    *   Czechoslovakia (1976)\n",
       "    *   Soviet Union (1960)"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Markdown(state[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "gemini-research",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
